Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 9
Submit an article Journal homepage
257
Views
38
CrossRef citations to date
0
Altmetric
Original Article

Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)

Michael Koenigsmann Hematology/Oncology Departments, University Magdeburg, GermanyCorrespondence[email protected]
,
Wolfgang U Knauf Free University Berlin, Germany
,
Michael Herold Klinikum Erfurt, Germany
,
Rita Pasold Ernst-von-Bergmann Hospital Potsdam, Germany
,
Gerd Müller Hematology Practice Magdeburg, Germany
,
Henning Eschenburg Hematology Practice, Güstrow, Germany
,
Christoph Kahl University Rostock, Germany
,
Volker Lakner Hematology Practice Rostock, Germany
,
Michael Aßmann Hospital Riesa, Germany
,
Kathleen Jentsch-Ullrich Hematology/Oncology Departments, University Magdeburg, Germany
,
Martin Mohren Free University Berlin, Germany
,
Rainer Bartsch Klinikum Erfurt, Germany
&
Astrid Franke Ernst-von-Bergmann Hospital Potsdam, Germany
 show all
Pages 1821-1827 | Received 04 Apr 2004, Published online: 03 Aug 2009

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Sara Steffanoni, Michele Ghielmini & Alden Moccia. (2015) Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. Expert Review of Anticancer Therapy 15:11, pages 1337-1349.
Read now
Enrico Derenzini, Pier Luigi Zinzani & Bruce D. Cheson. (2014) Bendamustine: role and evidence in lymphoma therapy, an overview. Leukemia & Lymphoma 55:7, pages 1471-1478.
Read now
Eva Walter, Thomas Schmitt,Sascha Dietrich, Anthony Ho & Mathias Witzens-Harig. (2012) Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leukemia & Lymphoma 53:11, pages 2290-2292.
Read now
Julie Elizabeth Chang & Brad Steven Kahl. (2012) Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 13:10, pages 1495-1505.
Read now
Nousheen Samad & Anas Younes. (2010) Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. OncoTargets and Therapy 3, pages 167-178.
Read now
Chaitra Ujjani & Bruce D Cheson. (2010) Bendamustine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 10:9, pages 1353-1365.
Read now
Peter Moosmann, Marc Heizmann, Nina Kotrubczik, Martin Wernli & Mario Bargetzi. (2010) Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leukemia & Lymphoma 51:1, pages 149-152.
Read now
Fredrick Hagemeister & George Manoukian. (2009) Bendamustine in the treatment of non-Hodgkin’s lymphomas. OncoTargets and Therapy 2, pages 269-279.
Read now
Ibrahim T Aldoss, Susan M Blumel & Philip J Bierman. (2009) The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma. Cancer Management and Research 1, pages 155-165.
Read now
Rudolf Weide. (2008) Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma. Therapeutics and Clinical Risk Management 4:4, pages 727-732.
Read now

Articles from other publishers (28)

Francesco Bertoni, Davide Rossi, Markus Raderer & Emanuele Zucca. (2020) Marginal Zone Lymphomas. The Cancer Journal 26:4, pages 336-347.
Crossref
Liat Vidal, Ronit Gurion, Liat Shargian, Martin Dreyling & Anat Gafter-Gvili. (2019) Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis. British Journal of Haematology.
Crossref
Corrado Tarella, Luca Arcaini, Luca Baldini, Giovanni Barosi, Atto Billio, Monia Marchetti, Alessandro Rambaldi, Umberto Vitolo, Pier Luigi Zinzani & Sante Tura. (2015) Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). Clinical Lymphoma Myeloma and Leukemia 15:2, pages 75-85.
Crossref
Amal A. El-MabhouhMary L. AyresElizabeth J. ShpallVeerabhadran Baladandayuthapani, Michael J. Keating, William G. Wierda & Varsha Gandhi. (2014) Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood 123:24, pages 3780-3789.
Crossref
Nobuya Hiraoka, Jiro Kikuchi, Takahiro Yamauchi, Daisuke Koyama, Taeko Wada, Mitsuyo Uesawa, Miyuki Akutsu, Shigehisa Mori, Yuichi Nakamura, Takanori Ueda, Yasuhiko Kano & Yusuke Furukawa. (2014) Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies. PLoS ONE 9:3, pages e90675.
Crossref
Liat Vidal, Anat Gafter-Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling & Ofer Shpilberg. (2012) Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews.
Crossref
Takahiro Motoki, Masato Asakura, Hiroaki Tanaka, Takakiyo Tatsumichi, Kazunori Yamaguchi, Hiroaki Ohnishi, Takuya Matsunaga, Shinji Kosaka, Noriyasu Fukuoka & Hitoshi Houchi. (2012) Successful Management of Adverse Events in a Case of Follicular Lymphoma Treated with Bendamustine as Outpatient Cancer Chemotherapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 38:9, pages 576-583.
Crossref
Mathias J. Rummel & Stephanie A. Gregory. (2011) Bendamustine's Emerging Role in the Management of Lymphoid Malignancies. Seminars in Hematology 48, pages S24-S36.
Crossref
Liat Vidal, Anat Gafter-Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling & Ofer Shpilberg. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Nishant Tageja. (2011) Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma. Clinical Medicine Insights: Oncology 5, pages CMO.S6085.
Crossref
Karly P. Garnock-Jones. (2010) Bendamustine. Drugs 70:13, pages 1703-1718.
Crossref
Nishant Tageja & Jasdeepa Nagi. (2010) Bendamustine: something old, something new. Cancer Chemotherapy and Pharmacology 66:3, pages 413-423.
Crossref
Bruce D. Cheson & Mathias J. Rummel. (2009) Bendamustine: Rebirth of an Old Drug. Journal of Clinical Oncology 27:9, pages 1492-1501.
Crossref
M. Schmidt-Hieber, A. Busse, B. Reufi, W. Knauf, E. Thiel & I. W. Blau. (2008) Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. Journal of Cancer Research and Clinical Oncology 135:2, pages 227-234.
Crossref
Trevor W. Dennie & Jill M. Kolesar. (2009) Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma. Clinical Therapeutics 31, pages 2290-2311.
Crossref
Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen Ganjoo, Michael E. Williams, Myron S. Czuczman, K. Sue Robinson, Robin Joyce, Richard H. van der Jagt & Bruce D. Cheson. (2009) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Cancer, pages NA-NA.
Crossref
Matt Kalaycio. (2008) Clinical Experience with Bendamustine: A New Treatment for Patients with Chronic Lymphocytic Leukemia. Clinical Leukemia 2:4, pages 223-229.
Crossref
Mathias Rummel. (2008) Considerations with Newer Regimens for Indolent Non–Hodgkin Lymphoma. Clinical Lymphoma and Myeloma 8, pages S128-S136.
Crossref
Dominic A. SolimandoJrJr & J. Aubrey Waddell. (2008) Bendamustine; Levoleucovorin. Hospital Pharmacy 43:8, pages 629-633.
Crossref
Stephen M. Ansell, David J. Inwards, Kendrith M. RowlandJr.Jr., Patrick J. Flynn, Roscoe F. Morton, Dennis F. MooreJr.Jr., Scott H. Kaufmann, Irene Ghobrial, Paul J. Kurtin, Matthew Maurer, Christine Allmer & Thomas E. Witzig. (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. Cancer 113:3, pages 508-514.
Crossref
Christos Apostolopoulos, Leandro Castellano, Justin Stebbing & Georgios Giamas. (2008) Bendamustine as a model for the activity of alkylating agents. Future Oncology 4:3, pages 323-332.
Crossref
Jonathan W. FriedbergPhilip CohenLing ChenK. Sue RobinsonAndres Forero-TorresAnn S. La CasceLuis E. FayadAlberto BessudoElber S. CamachoMichael E. WilliamsRichard H. van der JagtJennifer W. OliverBruce D. Cheson. (2008) Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study. Journal of Clinical Oncology 26:2, pages 204-210.
Crossref
Andres Forero-Torres & Mansoor N. Saleh. (2007) Bendamustine in Non-Hodgkin Lymphoma: The Double-Agent that Came from the Cold War. Clinical Lymphoma and Myeloma 8, pages S13-S17.
Crossref
M. Leithäuser & M. Freund. 2007. Therapiekonzepte Onkologie. Therapiekonzepte Onkologie 342 384 .
Barbel Seyfarth, Andreas Josting, Martin Dreyling & Norbert Schmitz. (2006) Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. British Journal of Haematology 133:1, pages 3-18.
Crossref
John Gerecitano & Owen A. O’Connor. 2006. Hodgkin’s and Non-Hodgkin’s Lymphoma. Hodgkin’s and Non-Hodgkin’s Lymphoma 413 460 .
Michael E Williams & John J Densmore. (2005) Biology and therapy of mantle cell lymphoma. Current Opinion in Oncology 17:5, pages 425-431.
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 22:4, pages 183-190.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.